Edward A. Faber

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · The Lancet Oncology · 2020 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Paul B. Jacobsen, Jennifer Le‐Rademacher, Heather Jim et al. · Biology of Blood and Marrow Transplantation · 2014 · 100 citations · Full text

Medicine, Hematology, Exercise Physiology +14

Multiple Myeloma, Version 1.2013

Kenneth C. Anderson, Melissa Alsina, William Bensinger et al. · Journal of the National Comprehensive Cancer Network · 2013 · 70 citations · Full text

Medicine, Oncology, Hematologic Oncology +16

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: <scp>LYRA</scp> study

Habte Yimer, Jason M. Melear, Edward A. Faber et al. · British Journal of Haematology · 2019 · 67 citations · Full text

Medicine, Pharmacotherapy, Cancer Pharmacology +16

Multiple Myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger et al. · Journal of the National Comprehensive Cancer Network · 2011 · 53 citations · Full text

Medicine, Hematology, Oncology +11